Unknown

Dataset Information

0

Tumor Necrosis Factor-α Trimer Disassembly and Inactivation via Peptide-Small Molecule Synergy.


ABSTRACT: Aberrant signaling by tumor necrosis factor-α (TNFα) is associated with inflammatory diseases that can be treated with engineered proteins that inhibit binding of this cytokine to cell-surface receptors. Despite these clinical successes, there is considerable interest in the development of smaller antagonists of TNFα-receptor interactions. We describe a new 29-residue α/β-peptide, a molecule that contains three β-amino acid residues and three α-aminoisobutryic acid (Aib) residues, that displays potent inhibition of TNFα binding to TNFα receptor 1 (TNFR1) and rescues cells from TNFα-induced death. The complement of nonproteinogenic residues renders this α/β-peptide highly resistant to proteolysis, relative to all-α analogues. The mechanism of inhibitory action of the new 29-mer involves disruption of the trimeric TNFα quaternary structure, which prevents productive binding to TNFα receptors. Unexpectedly, we discovered that peptide-induced trimer disruption can be promoted by structurally diverse small molecules, including a detergent commonly used during selection procedures. The discovery of this synergistic effect provides a new context for understanding previous reports on peptidic antagonists of TNFα-receptor interactions and suggests new avenues for future efforts to block signaling via proteins with an active form that is oligomeric, including other members of the TNFα family.

SUBMITTER: Checco JW 

PROVIDER: S-EPMC7654703 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor Necrosis Factor-α Trimer Disassembly and Inactivation via Peptide-Small Molecule Synergy.

Checco James W JW   Eddinger Geoffrey A GA   Rettko Nicholas J NJ   Chartier Alexander R AR   Gellman Samuel H SH  

ACS chemical biology 20200714 8


Aberrant signaling by tumor necrosis factor-α (TNFα) is associated with inflammatory diseases that can be treated with engineered proteins that inhibit binding of this cytokine to cell-surface receptors. Despite these clinical successes, there is considerable interest in the development of smaller antagonists of TNFα-receptor interactions. We describe a new 29-residue α/β-peptide, a molecule that contains three β-amino acid residues and three α-aminoisobutryic acid (Aib) residues, that displays  ...[more]

Similar Datasets

| S-EPMC4007440 | biostudies-literature
| S-EPMC9749406 | biostudies-literature
| S-EPMC9941324 | biostudies-literature
| S-EPMC3174010 | biostudies-literature
| S-EPMC2852963 | biostudies-literature
| S-EPMC11153517 | biostudies-literature
| S-EPMC4459904 | biostudies-literature
| S-EPMC7283243 | biostudies-literature
| 2154083 | ecrin-mdr-crc
| S-EPMC3588004 | biostudies-literature